Top Markets
Coin of the day
Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc.

OTLC
Rang in aandelen #30395
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage... Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Aandeelprijs
$0.03834
Laatst gesynchroniseerd: 2026-08-18
Marktkapitalisatie
$17.01M
Verandering (1 dag)
-4.15%
Verandering (1 jaar)
-24.82%
Land
US
Handel Oncotelic Therapeutics, Inc. (OTLC)

Categorie

Koersgeschiedenis voor Oncotelic Therapeutics, Inc. (OTLC)
Hoogste slotkoers: $0.04 op 2026-08-01

Laagste slotkoers: $1.13K op 1993-08-01
Koersgeschiedenis van Oncotelic Therapeutics, Inc. van 1993 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) -32.69%
2025 190.53%
2024 -20.32%
2023 -22.41%
2022 -69.52%
2021 -23.89%
2020 10.12%
2019 94.22%
2018 -42.06%
2017 -52.99%
2016 -55.78%
2015 -50.20%
2014 -33.92%
2013 -46.34%
2012 -62.10%
2011 -75.63%
2010 -81.77%
2009 63.41%
2008 -70.61%
2007 -50.93%
2006 16.57%
2005 -22.97%
2004 -35.60%
2003 628.33%
2002 -57.82%
2001 -63.45%
2000 -53.89%
1999 80.93%
1998 -47.29%
1997 -25.80%
1996 133.79%
1995 86.60%
1994 -25.42%
1993 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$527.89 35.09%
US
$996.61 51.72%
NL
$116.54 -19.94%
AU
$735.86 6.07%
CH
$257.75 14.92%
BE